Lidija Konta

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 514 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Development of the <scp>PG</scp>x‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing

Cathelijne H. van der Wouden, Mandy H. van Rhenen, Wafa O. M. Jama et al. · Clinical Pharmacology & Therapeutics · 2019 · 100 citations · Full text

Medicine, Genetics, Pharmacology +17

Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project

Kathrin Blagec, Rudolf Koopmann, Mandy Crommentuijn – van Rhenen et al. · Journal of the American Medical Informatics Association · 2018 · 95 citations · Full text

Computing, Health Informatics, Pharmacotherapy +17

Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries

Kathrin Blagec, Jesse J. Swen, Rudolf Koopmann et al. · PLoS ONE · 2022 · 43 citations · Full text

Computing, Health Informatics, Pharmacology +17

Isoniazid‐induced polyneuropathy in a tuberculosis patient – implication for individual risk stratification with genotyping?

Mark Stettner, Daniela Steinberger, Christian Hartmann et al. · Brain and Behavior · 2015 · 24 citations · Full text

Medicine, Molecular Genetics, Pharmacology +17